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Cognitive deficits, such as working memory (WM) impairment, are cardinal features of schizophrenia (1) that are present before the onset of psychosis and are independent of illness relapse (2) (3) (4) . These deficits are more accurate predictors of poor social and occupational function than psychotic symptoms (5) (6) (7) . Much attention has been focused on developing treatments to improve the executive functions of dorsolateral prefrontal cortex, which control and coordinate the many subprocesses necessary for WM (e.g., the ability to hold and manipulate information online). However, more recent electrophysiological evidence suggests that WM impairment in schizophrenia may arise in part from abnormalities in very early perceptual subprocesses.
Several studies report that patients with schizophrenia have reduced amplitude of early visual evoked response potentials (ERPs) as early as 100 ms after stimulus onset-the P100 potential (8) (9) (10) (11) . This may be a trait marker for vulnerability, as it has been reported in unaffected first-degree relatives (12) and high schizotypal individuals (13) . Koychev et al. (13) reported Q3 that P100 amplitude predicted performance during a visual WM task in healthy control subjects but was reduced in patients with early-onset schizophrenia. These P100 effects in patients were demonstrated to be independent of drug dosage or symptom severity (8) . Based on these and other data, it has been suggested that cognitive deficits in schizophrenia could involve abnormal sensory (i.e., bottom-up) processing (9) . An alternative view is that P100 reduction reflects abnormal modulation by higher order areas. This view is based on observations that P100 responses to more complex tasks may depend on recurrent feedback from higher cognitive areas (14, 15) . Direct evidence for prefrontal facilitation of P100 was provided by a study that showed reduced P100 to a bifield visual discrimination task in patients with prefrontal cortex lesions (16) and after a reversible experimental lesion induced by transcranial magnetic stimulation (17) .
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Several studies have reported that patients with schizophrenia have reduced amplitude of the P300 ERP component (18) (19) (20) . P300 potentials are typically evoked by infrequent target stimuli that differ in quality or duration from more frequent stimuli (21, 22) , but they are also elicited by WM tasks during both encoding and retrieval (23, 24) . P300 has been conceptualized as a neurophysiological correlate of WM update in response to changes in the environment (25) . Patients with schizophrenia show a reduction in P300 (20, 26, 27) , which has been shown to correlate with the level of cognitive impairment (28, 29) .
Changes in early visual processing in schizophrenia inevitably implicate abnormal cortical glutamate function in their pathogenesis. Indeed, the ability of noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine and ketamine to mimic symptoms, cognitive impairments, and electrophysiological changes of schizophrenia in healthy volunteers (30) (31) (32) (33) (34) has been key to the development of the NMDA-deficiency theory of schizophrenia (35) (36) (37) . The importance of glutamate to cognition was demonstrated by preclinical work showing that glutamate gated ion channels (NMDA and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid [AMPA] receptors) jointly modulate learning and memory (38) (39) (40) . Whereas AMPA has been suggested to be involved in the feedforward visual information transfer, NMDA receptor activity has been implicated in longer term changes in excitability that underlie experience-dependent learning and memory by modulating neurons that have already been depolarized by sensory input. The modulatory role of NMDA receptor activity has been investigated within visual (41, 42) and prefrontal (43, 44) cortices to study visual perception and WM, respectively. In addition, there is evidence that NMDA antagonism enhances AMPA-mediated responses and disrupts modulation of sensory cortex by top-down processes in humans (45) and primates (46) . In summary, ketamine has been shown to disrupt both early perceptual and WM processes in animals and human functional magnetic resonance imaging (fMRI) studies. However, there is surprisingly little known about the influence of ketamine on the neurophysiological changes measured with ERPs in the context of WM processes. Studies so far have focused on auditory oddball paradigms and reported reductions in P300 as well as a marker of automatic WM update, mismatch negativity (47) (48) (49) (50) . Visual experiments have focused exclusively on later ERP components, reporting an attenuation of the P300 component (51) (52) (53) .
In this study, we sought to address the gap in knowledge relating to the effects of ketamine on early visual processing and the impact these have on WM. We administered ketamine in a double-blind, placebo-controlled randomized design to a group of healthy volunteers and recorded continuous electroencephalograms (EEGs) while the volunteers performed a visual WM task. We predicted that ketamine would reproduce the early visual and higher cognitive WM deficits reported in schizophrenia. We expected that this would be evident in impaired cognitive performance as well as reduced P100 and P300 ERP amplitudes after ketamine administration. We reasoned that if the WM deficit associated with NMDA dysfunction is due to a disruption of early sensory information, this would be reflected in reduced P100 amplitude. In contrast, if the effects are due to later memory processing, we expected to see a change in the P300 amplitude.
METHODS AND MATERIALS

Participants
This study was approved by North West 5 Research Ethics Committee, Haydock Park, United Kingdom (Reference No. 10/H1010/3). Participants were recruited from a departmental database of volunteers who had completed the Schizotypal Personality Questionnaire (SPQ) (54) . Individuals scoring #42 [cutoff for high schizotypy based on a previous study in the same population (55) ] were invited to attend at the Manchester Wellcome Trust Clinical Research Facility, where they provided written consent for assessment and for testing. The participants completed the SPQ again and went through a medical and psychiatric history interview and physical examination (including electrocardiogram and body mass index measurement). Participants were selected if they were 18 to 55 years old with no personal or family history of psychotic mental illness and deemed to be healthy on physical assessment with a body mass index between 18 and 30. Exclusion criteria were SPQ score .42, pregnancy (positive urine dipstick), any concurrent medication aside from simple analgesia, history of severe allergic reaction to drugs, severe physical or mental illness, current alcohol or substance misuse or dependence, positive urine dipstick for illicit drugs, smoking more than five cigarettes per week, and consumption of more than six caffeinated drinks per day or any caffeinated drink in the 2 hours preceding the appointment. Included participants completed the National Adult Reading Test (56) to determine verbal IQ.
Experiment Design and WM Task
Forty-four participants met inclusion criteria and were randomly assigned to receive either placebo or ketamine in a double-blind design. Participants were seated in front of a monitor and familiarized themselves with the study task. Infusion with either ketamine or placebo began after a 20-minute EEG resting-state recording. Ketamine was administered at a rate allowing stable plasma concentration of 100 ng/ mL (57) . We used the Clements 250 infusion model,
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which was shown to reliably predict ketamine plasma concentrations (i.e., within 2 SD of the observed plasma concentration) (58) . To achieve the target plasma levels, the ketamine doses delivered were 0.16 mg/kg 6 0.0028 (mean 6 SD) during the first minute followed by approximately 0.39 mg/kg/hour (for 100 ng/mL target plasma concentration). The doses of ketamine were chosen on the basis that they would induce both subjective and cognitive subjective effects.
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Participants began the EEG task 5 minutes after the start of infusion ( Figure 1A ).
WM Task
The experiment consisted of a delayed matching-to-sample WM task with minor modifications from another experiment (59) described in full elsewhere (13) . Briefly, participants were instructed to remember one, two, or three abstract forms presented successively in the center of a black screen ( Figure 1B) . After a delay period, a new or previously presented form appeared on the screen, and the participants pressed a button indicating if they did or did not recognize the form from the sample (keyboard buttons "Y" or "N," respectively). To our knowledge, none of the participants had been exposed to a similar WM task or been part of studies testing cognition.
Each run lasted 6 minutes and consisted of 30 trials, 10 of each WM load intermixed pseudorandomly. Participants completed three blocks with a block made up of two runs (the runs were separated by a 2-minute resting trace). Blocks were separated by 10-minute breaks. We completed the Clinician Administered Dissociative Symptom Scale (CADSS) (60) during the first break and the Brief Psychiatric Rating Scale (BPRS) (61) during the second break. Physical observations including blood pressure, pulse, and temperature were recorded before testing commenced and after each block. On completion of the final block, the infusion was stopped. Participants were observed and their vital signs were recorded for a minimum of 2 hours before being discharged.
ERP Data Acquisition, Processing, and Analysis
Continuous EEG recording was obtained using the ActiveTwo BioSemi electrode system (BioSemi, Amsterdam, Netherlands) from 64 active scalp electrodes digitized at 512 Hz with an open passband from DC to 150 Hz. A detailed description of the BioSemi electrode referencing and grounding convention can be found at http://www.biosemi.com/faq/cms&drl.htm.
BESA version 5.2 (Brain Electrical Source Analysis, Gräfelf-ing, Germany) was used to analyze data using an average reference calculated over the scalp electrodes offline. Only trials in which participants responded correctly to the WM task were included in the analysis. Epoch trials were defined as 400-ms prestimulus to 1000-ms poststimulus with a baseline of 2100 ms to 0 ms. For the encoding phase, we analyzed the response to the last object to appear within the encoding series (object 1 in load 1, object 2 in load 2, and object 3 in load 3). For the retrieval phase, we analyzed the responses to the target image. All electrode channels were subjected to automatic artifact rejection to correct for blinks and saccades (thresholds for exclusion of vertical and horizontal movements were 6250 mV and 6150 mV, respectively). The continuous data were then examined for outstanding blink artifacts, which were removed manually. The trials that survived artifact correction were filtered with a high-pass filter of 0.3 Hz (6 dB/octave) and a low-pass filter of 30 Hz (24 dB/ octave). The mean percentages of retained trials (6 SD) for ketamine were 91.2% 6 6.7 (encoding) and 91.8% 6 10.1 (retrieval) and for saline were 97.8% 6 2.7 (encoding) and 98.5% 6 1.7 (retrieval).
Evoked Response Potentials P100. Averaged mean amplitude from five occipital electrodes was used (PO8, O2, O1, PO7, Oz) to analyze P100. P100 was calculated by extracting the mean amplitude of the 20-ms window centered on the mean P100 latency for each individual participant. The latter was established by examining the global field power and manually extracting the latency of the increases in activity corresponding to P100 peak.
P300. Based on the grand average, we measured P300 in a time window between 400 and 750 ms. We averaged the mean amplitude of three central parietal electrodes (P1, Pz, P2) for each WM load during encoding and retrieval.
Statistics
Repeated measures analysis of variance (ANOVA) with withinsubject factors of WM load (loads 1, 2, and 3) and a betweensubject factor of drug (ketamine and saline groups) was used to analyze reaction time (RT), percentage correct responses (accuracy), P100 amplitude, P100 latency, and P300 amplitude. This was done for encoding and retrieval stimuli separately. For the P300 models, we tested the hypothesis that P100 modulates the subsequent P300 signal by running a correlation between P100 and P300. We also ran a mixedmodel repeated measures ANOVA with a time-varying (WM load) covariate (P100) including P100 as a covariate separately for encoding and retrieval. Significant drug 3 WM load interactions were followed with linear post hoc analyses. Pearson's correlations were used to explore the relationship between an individual's overall cognitive performance (percentage correct responses on WM task across WM load) and the average of their ERP amplitudes (P100 and P300) as well as their clinical scores (CADSS and BPRS). The correlations were performed separately for the ketamine and placebo groups. 206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265   266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323 All participants completed six runs, grouped into three blocks. A block was made up of two runs interrupted by a 2-minute resting trace. After completion of the first block, participants rested and the Clinician Administered Dissociative Symptom Scale (CADSS) was scored. Following the second block, the Brief Psychiatric Rating Scale (BPRS) was administered during the rest. (B) Working memory (WM) paradigm. In the center of a black screen (0.6 3 0.6 visual angles), 36 nonnatural objects were presented. Participants were instructed to remember one, two, or three subsequently presented images. Each trial began with a screen saying "New trial," after which the encoding stimuli were presented for 400 ms each. The encoding images were separated by an interstimulus interval of 600 ms, during which a fixation cross appeared on the screen. After a delay (maintenance) period of 6 seconds, a target probe appeared on the screen (presentation time 3 seconds), and the participants had to indicate whether it was part of the initial sample set. The participants pressed "Y" if the target image was part of the encoding sequence and "N" if it was not. An interstimulus interval of 1 second separated the trials. 
RESULTS
Demographics and Questionnaire Data
The two groups did not differ statistically in terms of age, IQ score, SPQ score, and years of education ( Figure 2 ). There was also a significant negative correlation between CADSS scores and mean accuracy (r 5 2.578, p , .01) for the ketamine but not the placebo group (r 5 2.065, p 5 .78). These results were significant against a Bonferroni corrected critical value of 0.0125. RT increased with WM load for both groups (F 2,84 5 128.535, p , .001; partial eta 2 5 0.75), but this was not modified by ketamine.
ERP Results Encoding Phase P100 Amplitude. The mean latency and SE of the P100 component in encoding was 123.0 ms 6 2.9 for the ketamine group and 119.9 ms 6 3.0 for the placebo group. There was no effect of drug on latency. ERP Results Retrieval Phase P100 Amplitude. The P100 peaked at a latency of 116.4 ms 6 3.0 and 112.1 ms 6 3.0 for ketamine compared with control, Q7 respectively, with no main effect of drug. There was again a trend for the latency to be shorter with higher WM loads (F 2,84 5 2.69, p 5 .07). In the retrieval condition, ketamine significantly increased P100 amplitude relative to placebo (F 1,42 5 5.620, p 5 .02; partial eta 2 5 0.12). WM load did not have a significant effect on P100 amplitude, nor did it interact with drug. P100 amplitude correlated positively with mean WM accuracy over all three loads in the placebo group only (r 5 .48, p 5 .02). There was no significant correlation between BPRS and CADSS and P100 amplitude for either ketamine or placebo. P300 Amplitude. There was no main effect of drug in the P300 amplitude model, and a mixed-model repeated measures ANOVA with a time-varying covariate confirmed that this model was not modulated by P100. However, the interaction between drug and WM load approached significance (F 2,84 5 2.677, p 5 .08, partial eta 2 5 0.06). This was due to a larger P300 in the placebo group for WM loads 1 and 3 ( Figure 3D ). Q8 WM load exerted a significant main effect (F 2,84 5 15.310, p , .001, partial eta 2 5 0.27), which was due to a decrease in P300 amplitude with WM load. P300 amplitude in the retrieval phase correlated negatively with cognitive performance at trend in the ketamine group only (r 5 2.39, p 5 .08) (Figure 4 ).
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P300 did not correlate with either psychiatric rating scales or retrieval P100 for either of the two groups. ntial P100 and a significant load-dependent decrease in P300 amplitude during encoding. During retrieval, P100 was again significantly higher with ketamine, whereas P300 reduction with WM load differed only at trend level between the conditions. In addition, the amplitudes of P100 during retrieval correlated with cognitive performance in the placebo group with the effect disrupted by ketamine. Also, P300 under ketamine correlated negatively at trend with cognitive performance in both encoding and retrieval conditions.
P100 Effect
P100 amplitude was greater under ketamine than under placebo, which went against our prediction that the pattern observed in schizophrenia (8, (10) (11) (12) 59, 63) would be replicated. There are several potential ways to interpret our unexpected finding . A parsimonious explanation follows from   446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505   506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565 evidence that in visual cortex, NMDA receptors facilitate modulatory feedback through lateral connections, while AMPA underlies feedforward processes (46) . Preclinical research has shown that ketamine-induced NMDA blockade is associated with disinhibition of glutamate release and consequent activation of AMPA receptors (64, 65) . Furthermore, one parsimonious explanation is that NMDA hypofunction causes a disruption in the excitatory (glutamate) and inhibitory (gamma-aminobutyric acid) balance in the neural circuitry (37, 66) . Blocking NMDA leads to gamma-aminobutyric acidergic disinhibition and as a consequence to an increase in bottom-up stimulation of AMPA receptors. The dual glutamatergic effects of ketamine have been proposed as the basis of the ketamine-induced disruption of feature integration reported in humans (67) and animals (68) . Similarly, Self et al. (46) demonstrated in macaques that NMDA antagonism (using NMDA antagonist 2-amino-5-phosphonovalerate) disrupts recurrent but not feedforward processing in V1. Therefore, the ketamine-induced P100 augmentation shown here could be due to loss of lateral NMDA modulation and a potentiation of feedforward, AMPA-mediated processes. In line with this idea is the observation that under ketamine participants report heightened perceptual experiences (69).   566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616  617  618  619  620  621  622  623  624  625   626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645  646  647  648  649  650  651  652  653  654  655  656  657  658  659  660  661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683  684 (black line) and placebo groups (gray lines). There was no significant difference between the groups in terms of reaction times (A), although ketamine was associated with a more significant decrease in WM performance with increase in WM load relative to placebo (B). Error bars represent SE. An alternative or perhaps complementary explanation is based on evidence that P100 is under attentional (i.e., topdown) control (70) . Within the framework of predictive coding, it has been suggested that ketamine impairs top-down predictions but increases abnormal prediction error responses by stimulating AMPA (64, 71) . Early positron emission tomography metabolic mapping studies reported that ketamine focally increased prefrontal cortex metabolism (glucose uptake), probably by disinhibiting local glutamate release (72) (73) (74) . Furthermore, the functional impact of disinhibition has also been shown to alter global connectivity and an inability of the default mode network to disengage during WM performance (75) . This has been shown to be associated with impaired WM performance (76) . A noisier signal and disinhibition of long-range facilitatory projections to occipital cortex from prefrontal cortex could thus account for the increased P100 amplitude we observed.
If fronto-occipital disinhibition does occur under ketamine, a critical difference may be present between this state and established schizophrenia. Using the same paradigm, we recently showed reduced functional connectivity between ventrolateral prefrontal cortex and extrastriate visual areas on fMRI in patients with schizophrenia compared with control subjects (77) . One possibility is that ketamine models a state of acute NMDA impairment in early psychosis in which frontal disinhibition may occur. In contrast, in chronic psychosis, frontal cortex function is inhibited, potentially as a result of chronic glutamate dysfunction. In direct support of this view , a   686  687  688  689  690  691  692  693  694  695  696  697  698  699  700  701  702  703  704  705  706  707  708  709  710  711  712  713  714  715  716  717  718  719  720  721  722  723  724  725  726  727  728  729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745   746  747  748  749  750  751  752  753  754  755  756  757  758  759  760  761  762  763  764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780  781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804 (78) . However, any decisive interpretation of the net effect of ketamine is likely to be an oversimplification. It is not possible to identify with confidence the net effect of ketamine on visual cortical function on the basis of our finding. Using fMRI, we have shown that ketamine causes complex temporal and regional blood oxygen level-dependent changes, including hypoactivation and hyperactivation with the prefrontal and parietal cortices preferentially affected (79) . This is in line with EEG studies that have demonstrated increases in highfrequency and decreases in low-frequency neural oscillations in humans (80) and in mice (81) . In addition, resting-state positron emission tomography studies have demonstrated that ketamine-induced increase in regional blood flow is counterintuitively associated with reduced oxygen extraction (82, 83) , possibly related to the direct vascular effect of ketamine (84) .
Whatever the exact genesis of the P100 increase under ketamine, the present study suggests that while acute ketamine challenge may recreate a facet of the core pathophysiology in psychosis, it is unlikely to be capturing the changing role of glutamate subsystems in the evolution of the illness. Given the evidence for decreasing frontal glutamate levels with age in patients with schizophrenia (85) , further P100 studies specifically targeting patients early in the disease are needed to further test the hypothesis that ketamine recreates states typical for the initial, but not chronic stages, of psychotic illness [see also (78) ].
P300
We found that ketamine was associated with a decrease in P300 amplitude with WM load exertion. This finding is consistent with previous studies in the auditory and visual domains (47) (48) (49) (50) (51) (52) (53) 86 ) although we observed a strong effect only in the encoding phase with the retrieval significance reduced to a trend. We also found a trend for correlation between P300 and cognitive performance under ketamine for both encoding and retrieval conditions. A study using EEG space source localization and fMRI showed that ketamine extinguished primarily the parietal locus of the frontoparietal network generating P300 (51) . This is in agreement with other studies showing that ketamine preferentially attenuates the parietally generated P300b component,
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which is understood to be an index of top-down allocation of attentional resources (26) and WM update (24) . We did not find evidence that P300 was directly modulated by the earlier P100-this is based on the lack of a significant covariate effect of P100 in the P300 analyses. These results argue that ketamine disrupts P300 through direct effects on the parietal cortex processes rather than solely as a consequence of its action on the visual cortex.
Limitations
An inherent limitation to nearly all ketamine experiment designs is that the extent to which researchers are blinded is limited by the obvious subjective effects of ketamine.
We sought to remedy this by having separate study personnel record and process the EEG data (A. Shepherd and I. Koychev, respectively).
Conclusions
This is the first study to explore the effects of ketamine on early visual processing in WM in healthy volunteers. We found evidence of a dysfunctional increase in early visual P100 amplitude. This finding contrasts with reduced P100 amplitudes reported in chronic schizophrenia as well as in individuals with familial or personality trait vulnerability.
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This may suggest that while acute ketamine captures some of the phenomenological features of psychosis, it does not fully replicate the neurochemical basis of cognitive deficits associated with the chronic condition. Visual P100 studies in early psychosis are required to test the hypothesis that hyperglutamatergic states similar to the ones caused by ketamine occur only in the earliest disease stages. The study also replicated cognitive deficits and P300 reduction with ketamine. The current findings provide insight into the critical differences between established psychotic illness and its best validated pharmacological model.
ACKNOWLEDGMENTS AND DISCLOSURES
This work was supported
Q12
by the Welsh Institute of Cognitive Neuroscience and CONICYT, Chile, Basal Project FB0008 (to WE-D).
We thank the Manchester Wellcome Trust Clinical Research Facility for their facility and personnel supporting the study and Dr. Andrew Shepherd for his technical assistance in running the study. Neither the study sponsor (The University of Manchester) nor the co-funder (Welsh Institute of Cognitive Neuroscience) had any role in data analysis or manuscript preparation.
